Abstract:Objective To evaluate the efficacy and safety of different dosage of spironolactone on normal renal func -tion in patients with congestive heart failure .Methods From 2011 December to 2012 December , 148 patients with systolic heart failure and normal renal function were enrolled , on the basis of conventional therapy , they were randomly divided into spironolactone 20 mg group with 72 cases, spironolactone 60 mg group with 76 cases.B-type natriuretic peptide (BNP) level were measured in all patients before and after 12 months of treatment , and ultrasound were performed to assess the change of left ventricular end diastolic volume index (LVEDVI), left ventricular end systolic volume index (LVESVI), left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF).And the serum potassium, renal function and adverse events were monitored in all of these patients .Results After 12 months of treatment, 2 groups of LVEDVI, LVESVI, LVMI, LVEF and BNP were significantly improved than before treatment ( P <0.05), 60 mg group were more significant than the 20 mg group, the difference was statistically significant ( P <0.05).The increase of hyperkalemia (potassium is more than or equal to 5.5 mmol/L) in the 60 mg group was not significant as in the 20 mg group (7.9%vs.2.8%), no significant diffe-rence was found ( P >0.05).Severe hyperkalemia (potassium is more than or equal to 6 mmol/L) were not detected in both of the 2 groups.The incidence of hypokalemia in 20 mg group was significantly than in 60 mg group (2.6% vs.11.1%), and the difference was statistically significant ( P <0.05).Breast development and breast pain were significantly higher in 60 mg group than in 20 mg group (13.2%vs.2.8%), and the difference was statistically significant ( P <0.05).2 cases with serum creatinine increased >50%than previous test were found in each of the 2 group, no significant difference were found ( P >0.05), there was no serum creatinine increase >180 μmol/L case was found in both of the two gruops .Conclusion On the basis of conventional therapy , spironolactone 60 mg under close monitoring is safe and can further improve ventricular remodeling , reduce the level of BNP and reduce the hypokalemia occurred in patients with congestive heart failure and normal renal function .

The effect of spironolactone on some neurohormonal factors in patients suffering cardiac insufficiency secon-dary to dilated cardiomyopathy

Effect of Spironolactone on Some Neurohormonal Factors in Elderly Patients Suffering Cardiac Insufficiency Secondary to Hypertension

Effects of Spironolactone on Plasma Level of BNP and Cardiac Function in CHF Patients

Low Dose Spironolactone Alleviates Cardiac Remolding in Patients with NYHA Daass Ⅰ - Ⅱ Heart Failure

The effects of Spironolactone on vascular endothelium function in patients with CHF

Effects of Pravastatin on Cardiac Function and Plasma Level of Brain Natriuretic Peptide in Patients with Chronic Heart Failure

Effect of Aldosterone Receptor Antagonist on the Treatment of Patients with Dilated Cardiomyopathy

Efficacy and safety of different doses of spironolactone in systolic heart failure patients with normal renal function

Efficacy and safety of spironolactone in systolic heart failure patients with mild renal dysfunction

Eeffect of Spironolactone on Ventricular Remodeling in Patients with Asymptomatic Left Ventricular Systolic Dysfunction

Effects of Spironolactone on the Left Ventricular Remodeling In Renovascular Hypertension Rats

Effects of Spironolactone on Dialysis Patients with Refractory Hypertension: a Randomized Controlled Study.

Effect of spironolactone on cardiac remodeling after acute myocardial infarction

Retrospective study on the short-term efficacy of different doses of Spironolactone in patients with heart failure of ischemic cardiomyopath and the influence of ventricular remodeling markers

Effect of Spironolactone Pretreatment on the Expression of Endothelial Nitric Oxide Synthase in Rabbit Coronary Artery of Non-Infarcted Area and the Hemodynamics after Myocardial Infarction

Spironolactone Improves Myocardial Fibrosis in Spontaneously Hypertensive Rats

Small doses of spironolactone decrease the levels of BNP and hs-CRP of patients with acute myocardial infraction

Influence of perindopril combining spironolactone on neuroendocrine in treatment of chronic heart failure

Protective Effect of Spironolactone on Myocardium During Perioperation Period of Percataneous Coronary Intervention

The mechanism of spironolactone against calcineurin-dependent cardiac hypertrophy in renal hypertension rats

The effect of spironolactone on the levels of GATA4 protein and hypoxia inducible factor-1α in patients receiving coronary stent implantation